*Clinical Infectious Diseases*

BRIEF REPORT

# Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection

**Tongai G. Maponga,[1] Montenique Jeffries,[2] Houriiyah Tegally,[3] Andrew Sutherland,[1] Eduan Wilkinson,[6] Richard J. Lessells,[3] Nokukhanya Msomi,[4] Gert van Zyl,[1,5] Tulio de Oliveira,[3,6,7] and Wolfgang Preiser[1,5]**

[1]Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa; [2]Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa; [3]KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; [4]Discipline of Virology, School of Laboratory Medicine and Medical Sciences and National Health Laboratory Service (NHLS), University of KwaZulu–Natal, Durban, South Africa; [5]National Health Laboratory Service, Tygerberg Business Unit, Cape Town, South Africa; [6]Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa; and [7]Department of Global Health, University of Washington, Seattle, Washington, USA

A 22-year-old woman with uncontrolled advanced human immunodeficiency virus (HIV) infection was persistently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) beta variant for 9 months, the virus accumulating >20 additional mutations. Antiretroviral therapy suppressed HIV and cleared SARS-CoV-2 within 6 to 9 weeks. Increased vigilance is warranted to benefit affected individuals and prevent the emergence of novel SARS-CoV-2 variants.

**Keywords.** SARS-CoV-2; uncontrolled HIV infection; immunocompromised; antiretroviral therapy; persistent infection.

In the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, South Africa so far has experienced 4 distinct waves of infections, each driven by different variants. The first wave between June and August 2020 was attributed to a mix of SARS-CoV-2 lineages with low overall diversity; the second wave lasted from November 2020 until February 2021 and was driven by the beta variant of concern (VOC) (B.1.351); the third wave was dominated by the delta VOC (B.1.617.2) and occurred from May until October 2021. The most recent fourth wave, beginning in November 2021, was driven by the omicron VOC (B.1.1.529) [1].

The origins of new divergent variants are not yet understood. One hypothesis is that they arise in severely immunocompromised individuals, such as patients receiving cancer chemotherapy, organ transplant recipients, and people with uncontrolled advanced HIV disease. Failure to clear SARS-CoV-2 because of suboptimal immune responses results in persistent infections that allow the accumulation of mutations that may confer immune evasive properties [2].

We here describe a case of persistent SARS-CoV-2 infection, lasting for a minimum of 9 months, in a severely immunocompromised person with HIV that had challenges with adherence to antiretroviral therapy. This case report was approved by the Health Research Ethics Committee of Stellenbosch University and the patient provided informed consent.

## CASE DETAILS, METHODS, AND RESULTS

An outpatient HIV-infected woman in her 20s first tested positive for SARS-CoV-2 by polymerase chain reaction on a respiratory sample while resident in a rural area of KwaZulu-Natal province of South Africa in January 2021. She was tested on the Allplex SARS-CoV-2 assay (Seegene Inc., Seoul, Republic of Korea) with threshold cycle (Ct) values of 18, 20, and 22 for the E, RdRp, and N gene targets, respectively. Her SARS-CoV-2 infection was asymptomatic and she did not receive any COVID-19-related treatment. At the time, her CD4 count was 91 cells/μL and her plasma HIV RNA 5.07 $\log_{10}$ viral RNA copies/mL. She had had HIV from birth and was on an antiretroviral therapy (ART) regimen comprising tenofovir, emtricitabine, and efavirenz.

In August 2021, she had moved from KwaZulu-Natal to Cape Town, Western Cape province, South Africa. There she was admitted with stridor to a tertiary hospital in mid-September 2021, with a 1-week history of sore throat, malaise, poor appetite, and dysphagia. She reported not being vaccinated against COVID-19.

On physical examination, the patient was wasted but had no palpable lymph nodes. She was awake and lucid, with no focal neurological deficits. She was not in respiratory distress, had normal breath sounds with no crackles or wheezes audible, and an oxygen saturation of 98% on room air. The cardiovascular and abdominal examinations, renal function, white cell count, and liver enzymes were without abnormalities. Her CD4 count was 9 cells/μL and her plasma HIV RNA 4.60 $\log_{10}$ viral RNA copies/mL, indicating advanced HIV infection, poorly controlled by ART because of self-reported challenges with adherence. Following adherence counselling,

Received 25 January 2022; editorial decision 27 June 2022; published online 6 July 2022

Correspondence: T. G. Maponga, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Avenue, Tygerberg, 7505, Cape Town, South Africa (tongai@sun.ac.za).

**Clinical Infectious Diseases®**



https://doi.org/10.1093/cid/ciac548

antiretroviral therapy was reinitiated 1 week after admission with a new ART regimen of tenofovir, efavirenz, and dolutegravir.

During a prolonged hospital stay, the patient experienced multiple complications, developing middle cerebral artery (MCA) stroke and nosocomial pneumonia requiring treatment. As part of clinical workup to determine the cause of her stridor, a nasopharyngeal swab obtained on 25 September 2021 tested positive by the Alinity m SARS-CoV-2 routine diagnostic assay (Abbott Park, Illinois, USA); the Ct of 16 suggested a relatively high viral RNA load. The sample was serendipitously included in ongoing routine genomic surveillance [3], using Oxford Nanopore Technologies sequencing on the Nanopore GridION using ARCTIC version 3 primers as previously described [4]. The viral sequence belonged to the B.1.351 lineage (GISAID accession: EPI_ISL_5018695) and was therefore flagged for further investigation, for the beta VOC was at that time responsible for <1% of genomically confirmed cases and its evolution being monitored closely by members of the Network for Genomic Surveillance in South Africa (NGS-SA).

A second nasopharyngeal swab, obtained a month later on 26 October 2021 while the patient was still hospitalized, again tested positive, with Ct values by the Cepheid GeneXpert SARS-CoV-2 assay (Sunnyvale, California, USA) of 15.3 for the E-gene and 18.2 for the N-gene targets, suggestive of a persisting high viral RNA load. Genomic sequencing of the virus using Nanopore sequencing again revealed B.1.351 (GISAID accession: EPI_ISL_6227177). In addition, virus was isolated on Vero E6 cells. After the patient revealed her first positive SARS-CoV-2 test from January 2021, the archived sample was sequenced using published methods [1] that revealed B.1.351 (GISAID accession: EPI_ISL_6585229).

Another month later (while still hospitalized), on 25 November 2021, the patient's HIV viral load was <50 copies/mL and another nasopharyngeal SARS-CoV-2 PCR test was negative. Unfortunately, a CD4 count was not performed but suppressed HIV replication and clearance of SARS-CoV-2 infection suggest some degree of immune reconstitution at that stage. Antibodies against SARS-CoV-2 nucleocapsid and spike proteins also were not measured. The patient was subsequently discharged from our hospital to a different facility for rehabilitation.

The 3 genome sequences from the patient were analyzed against a global reference dataset of 7977 genomes, including 366 from South Africa, using a custom build of the SARS-CoV-2 NextStrain (https://github.com/nextstrain/ncov). The workflow performs alignment of genomes, phylogenetic tree inference, tree dating, and ancestral state construction and annotation. The phylogenetic tree (Figure 1) was visualized using ggplot and ggtree.

Phylogenetic analysis confirmed that the infecting virus from all 3 swabs clustered together on a background of 7977 other SARS-CoV-2 sequences, which confirms persistent infection over at least 9 months rather than reinfection. Over this period, the virus acquired at least 10 mutations in the spike glycoprotein and 11 mutations outside spike over and above the lineage-defining mutations for beta, as shown in Figure 1. The additional spike mutations included six in the spike receptor-binding domain (S371F, N450D, A475V, F490Y, S494P, and Q498R); a deletion of amino acids residues 141–143 of the N-terminal domain (NTD) that leads to neutralizing antibody escape [5] and that seems to be frequently observed in chronic infections; and 2 substitutions in the S2 domain (D737Y and F888L). Because of a gap in the NTD sequence, it is not known whether a further substitution (N30T) in the NTD may have been present from the beginning. We observed a reversion of some of the mutations between the first and second sequences generated in Cape Town, with the spike N30T and spike F888L present in the September sample but not detected in the October one.

## DISCUSSION

Our case adds to the evidence that severe immunosuppression associated with uncontrolled HIV infection may lead to chronic SARS-CoV-2 infections [6–8]. These persistent infections not only allow continued shedding of infectious virions but also lead to the accumulation of mutations, some of which lead to immune escape that may result in emergence of new variants [9, 10]. Therefore, it is important that countries that have a high burden of HIV infection should encourage prompt diagnosis and treatment of HIV infections and compliance with antiretroviral therapy for those already receiving treatment to reduce the risk of persistent SARS-CoV-2 infections and continued shedding of infectious virus that pose a threat to controlling the pandemic.

The additional mutations in the receptor-binding domain of the spike glycoprotein (S371F, N450D, A475V, F490Y, S494P, and Q498R) in the later genomes are at sites associated with escape from all 4 classes of neutralizing antibodies [11]. We observed similar mutations at spike positions 475 and 490 in the other case we reported of chronic SARS-CoV-2 infection in association with advanced HIV [7, 10]. It is also notable that these mutations are identical or at the same position as mutations in other variants of concern/interest (Q498R and S371L in omicron; and F490Y in lambda).

The point needs to be made, however, that no genomes identical to or originating from the September or October ones were identified by the wider genomic surveillance. Although genomic surveillance efforts may well miss viruses occurring at low frequencies, because of low testing rates and low and patchy coverage of genomic surveillance, a "successful" new variant would likely increase over time and not escape detection for weeks or months. The history of the detection of the novel Omicron variant here in South Africa supports this notion [1].




**Figure 1.** Clinical time-course and phylogenetic analysis of 3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole-genome sequences from case with prolonged infection with the beta variant of concern (VOC) of SARS-CoV-2. *A*, Time course showing major clinical events during the period of prolonged infection with SARS-CoV-2, starting with initial positive test in the KwaZulu-Natal province followed by period of hospitalization in the Western Cape and eventual discharge from Tygerberg Hospital. *B*, Timed maximum-likelihood phylogenetic tree with patient sequences (yellow) at 3 time-points (January 2021: hCoV-19/South Africa/CERI-KRISP-K029499/2021, GISAID accession ID: EPI_ISL_6585229; September 2021: hCoV-19/South Africa/Tygerberg_2777/2021, GISAID accession ID: EPI_ISL_5018695; October 2021 hCoV-19/South Africa/Tygerberg_2967/2021, GISAID accession ID: EPI_ISL_6227177) in relation to 336 representative South African and 7641 other global sequences. The zoomed-in view shows the finer phylogenetic relationship between the 3 patient-derived sequences. Spike mutations accumulated in addition to the known beta mutations are labeled. Abbreviations: HIV, human immunodeficiency virus; MCA, middle cerebral artery.

There is thus no evidence that the evolved variants from this case successfully spread into the general population. This case, like others before, describes a potential pathway for the emergence of novel variants but it does not prove that any of the variants detected so far did originate from such a persistent infection in a severely immunocompromised host.

This case furthermore highlights the value of well-coordinated and thoroughly established genomic surveillance efforts. Fortuitously, the September sample from this patient was sequenced as part of the NGS-SA effort. It was flagged as warranting further investigation as a beta variant that, by that stage, had become rare by the sequencing and sequence analysis teams who contacted the diagnostic virologists and those the requesting clinician. Good connections between sequencing laboratories, routine diagnostic laboratories, and frontline clinicians are indispensable to identify and investigate such cases.

Once again, our experience reinforces previous reports that effective ART is the key to controlling such events. Once HIV replication is brought under control and immune reconstitution commences, rapid clearance of SARS-CoV-2 is achieved, probably even before full immune reconstitution occurs. This underscores the broader point that gaps in the HIV care cascade need to be closed, which will benefit other conditions and public health problems, too, including COVID-19 [12].

## Notes

***Acknowledgments.*** The authors gratefully acknowledge the work of the frontline clinical staff in caring for the patient. The authors thank Shannon Wilson, Dr Kamela Mahlakwane, Mathilda Claassen, and the NHLS Tygerberg Virology staff for the SARS-CoV-2 test data and data capturing, and the members and contributors of the Network for Genomic Surveillance in South Africa (NGS-SA) for support and discussions.

***Financial support.*** This work was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation, the Poliomyelitis Research Foundation, and the National Health Laboratory Service Research Trust. The funders had no role in the conception, conduct or the writing of the paper.

***Potential conflicts of interest.*** The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

## References

1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature **2022**; 603:679–86. doi:10.1038/s41586-022-04411-y. Epub ahead of print.
2. Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med **2021**; 385:562–6. doi:10.1056/NEJMsb2104756
3. Msomi N, Mlisana K, de Oliveira T, Network for Genomic Surveillance in South Africa writing group. A genomics network established to respond rapidly to public health threats in South Africa. Lancet Microbe **2020**; 1:e229–30. doi:10.1016/S2666-5247(20)30116-6
4. Engelbrecht S, Delaney K, Kleinhans B, et al. Multiple early introductions of SARS-CoV-2 to cape town, South Africa. Viruses **2021**; 13:526. doi:10.3390/v13030526
5. McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell **2021**; 184:2332–47.e16. doi:10.1016/j.cell.2021.03.028
6. Hoffman SA, Costales C, Sahoo MK, et al. SARS-CoV-2 neutralization resistance mutations in patient with HIV/AIDS, California, USA. Emerg Infect Dis **2021**; 27:2720–3. doi:10.3201/eid2710.211461
7. Karim F, Moosa MYS, Gosnell BI, et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv 2021.06.03.21258228. doi:10.1101/2021.06.03.21258228
8. Riddell AC, Kele B, Harris K, et al. Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease. Clin Infect Dis **2022**: ciac409. doi:10.1093/cid/ciac409
9. Tarhini H, Recoing A, Bridier-Nahmias A, et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: From prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis **2021**; 223:1522–7. doi:10.1093/infdis/jiab075
10. Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe **2022**; 30:154–62.e5 Jan 14. In Press, Journal Pre-proof. doi:10.1016/j.chom.2022.01.005
11. Greaney AJ, Starr TN, Barnes CO, et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun **2021**; 12:4196. doi:10.1038/s41467-021-24435-8
12. Msomi N, Lessells R, Mlisana K, de Oliveira T. Africa: tackle HIV and COVID-19 together. Nature **2021**; 600:33–6. doi:10.1038/d41586-021-03546-8